HUP0203303A3 - Compositions for administering taxanes orally to human patients - Google Patents

Compositions for administering taxanes orally to human patients

Info

Publication number
HUP0203303A3
HUP0203303A3 HU0203303A HUP0203303A HUP0203303A3 HU P0203303 A3 HUP0203303 A3 HU P0203303A3 HU 0203303 A HU0203303 A HU 0203303A HU P0203303 A HUP0203303 A HU P0203303A HU P0203303 A3 HUP0203303 A3 HU P0203303A3
Authority
HU
Hungary
Prior art keywords
compositions
human patients
administering taxanes
taxanes orally
orally
Prior art date
Application number
HU0203303A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of HUP0203303A2 publication Critical patent/HUP0203303A2/hu
Publication of HUP0203303A3 publication Critical patent/HUP0203303A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0203303A 1999-10-27 2000-10-27 Compositions for administering taxanes orally to human patients HUP0203303A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16231099P 1999-10-27 1999-10-27
PCT/US2000/029633 WO2001030448A1 (en) 1999-10-27 2000-10-27 Method and compositions for administering taxanes orally to human patients

Publications (2)

Publication Number Publication Date
HUP0203303A2 HUP0203303A2 (hu) 2003-02-28
HUP0203303A3 true HUP0203303A3 (en) 2005-01-28

Family

ID=22585092

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203303A HUP0203303A3 (en) 1999-10-27 2000-10-27 Compositions for administering taxanes orally to human patients

Country Status (18)

Country Link
EP (1) EP1225956A1 (de)
JP (1) JP2003512443A (de)
KR (1) KR20030019296A (de)
CN (1) CN1450923A (de)
AU (1) AU1104201A (de)
BR (1) BR0015149A (de)
CA (1) CA2389583A1 (de)
CO (1) CO5251425A1 (de)
CZ (1) CZ20021484A3 (de)
HU (1) HUP0203303A3 (de)
IL (1) IL149360A0 (de)
MX (1) MXPA02004164A (de)
NO (1) NO20022008L (de)
PL (1) PL354777A1 (de)
RU (1) RU2002113659A (de)
SK (1) SK5822002A3 (de)
WO (1) WO2001030448A1 (de)
ZA (1) ZA200203358B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
WO2002043765A2 (en) 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
CA2504268A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
CN101513395B (zh) * 2008-02-20 2011-01-12 单宝华 紫杉醇类双层软胶囊口服制剂药物
US9402812B2 (en) 2009-09-23 2016-08-02 Indu JAVERI Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
KR101752944B1 (ko) 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
EP4059497A1 (de) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitoren zur behandlung von hypersensitivitätsreaktionen auf taxane
EP4308114A1 (de) * 2021-03-17 2024-01-24 Dompe' Farmaceutici SpA C5ar1-inhibitoren zur behandlung von überempfindlichkeitsreaktionen gegen taxane

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
JP2000512997A (ja) * 1996-06-17 2000-10-03 イーライ・リリー・アンド・カンパニー 薬物耐性および多薬物耐性調節物質
HUP0003546A3 (en) * 1997-05-27 2002-12-28 Baker Norton Pharma Compositions for administering taxanes orally to human patients
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN100341485C (zh) * 1998-04-01 2007-10-10 斯凯伊药品加拿大公司 抗癌组合物
CA2684454A1 (en) * 1999-05-21 2000-11-18 American Bioscience, Llc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Also Published As

Publication number Publication date
PL354777A1 (en) 2004-02-23
NO20022008L (no) 2002-06-19
JP2003512443A (ja) 2003-04-02
HUP0203303A2 (hu) 2003-02-28
WO2001030448A1 (en) 2001-05-03
CA2389583A1 (en) 2001-05-03
CO5251425A1 (es) 2003-02-28
ZA200203358B (en) 2003-04-29
SK5822002A3 (en) 2003-01-09
BR0015149A (pt) 2002-10-29
NO20022008D0 (no) 2002-04-26
RU2002113659A (ru) 2004-01-27
IL149360A0 (en) 2002-11-10
CZ20021484A3 (cs) 2003-12-17
EP1225956A1 (de) 2002-07-31
AU1104201A (en) 2001-05-08
CN1450923A (zh) 2003-10-22
KR20030019296A (ko) 2003-03-06
MXPA02004164A (es) 2002-10-17

Similar Documents

Publication Publication Date Title
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
PL356358A1 (en) Solid dosage form of someticone for oral administration
HUP0002512A3 (en) Medicinal compositions for application to mucosa
HK1149719A1 (en) Ciclesonide contained pharmaceutical composition for application to mucosa
HUP0203303A3 (en) Compositions for administering taxanes orally to human patients
AU3469400A (en) Pharmaceutical compositions for treatment of diseased tissues
HUP0003546A3 (en) Compositions for administering taxanes orally to human patients
HUP0203311A3 (en) New pharmaceutical compositions of prolonged effect
IL166337A0 (en) Oral administration of calctionin
GB2355656B (en) Pharmaceutical compositions for oral and topical administration
IL145559A0 (en) Tolperison-containing pharmaceutical preparation for oral administration
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
HUP0201667A3 (en) Oral form of administration
AU1732401A (en) Medicinal compositions for oral use
IL149422A0 (en) Oral pharmaceutical compositions for liver therapy
HUP0400495A3 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
GB9910865D0 (en) Improvements relating to medical syringes
EP1210935A4 (de) Arzneimittel zur oralen anwendung
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions
AU2002229468A1 (en) Oral capsule for administering tablets to animals
EP1188440A4 (de) Medizinische zusammensetzungen zur oralen verabreichung
HUP0400075A2 (hu) AHDH kezelésére alkalmas gyógyászati készítmények előállítása
HUP0400007A2 (hu) Alkanoil-L-karnitin alkalmazása anhedónia kezelésére szolgáló gyógyászati készítmény előállítására
HUP9903735A3 (en) Use of indazolo derivatives for producing pharmaceutical compositions for treatment heart failure
GB9930266D0 (en) Oral administration of beneficial substances